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advantages for extrapleural pneumo-
nectomy (EPP) compared with chemo-
therapy alone,1 although several biases 
had influenced those results.2 After the 
MARS trial was published, EPP has 
been abandoned in many European 
countries.
Recently, several series demon-
strated comparable or sometime better 
results for pleurectomy decortication 
(PD) compared with EPP in terms of 
overall survival and quality of life.3,4 
As showed by the paper published by 
Lang-Lazdunski et al., the macroscopic 
complete resection was an independent 
prognostic factor for survival and not 
the type of surgery, and also the group 
of patients underwent an incomplete 
resection after PD had similar results 
in terms of survival compared with 
patients underwent to EPP.3 Considering 
the role of surgery in mesothelioma 
multimodality treatment and the impact 
of EPP on the quality of life, PD should 
be favored compared with EPP as surgi-
cal treatment of choice. EPP is still per-
formed in very highly selected patients 
with no evidence of nodal disease and 
when a complete macroscopic resection 
can be achieved.1,3
Most of the patients included in 
our analysis were treated before the 
MARS trial results were available; 
at that time the decision of perform-
ing EPP versus PD was driven by the 
patient’s operative risk and mainly by 
the intraoperative assessment of the 
extension of the tumor to achieve aim-
ing a complete macroscopic esection.
As we know the clinical staging is 
unreliable, and many patients are under 
staged, making difficult the compari-
son of different groups.5,6 In our study, 
clinical staging was missing in 854 out 
of 1365 patients (62.6%); in patients 
not treated surgically the impact of 
missing data was higher (634 of 862 
[73.5%] patients). Due to lack of data 
and accuracy of the clinical staging, we 
did not include the clinical stage in the 
univariate and multivariate analysis. We 
do not believe that this a methodologi-
cal bias, but excluding this factor from 
the analysis had improved the quality of 
the comparison between the nonsurgi-
cal and the surgical groups. The clinical 
staging would have represented a con-
founding factor.
staging (in general) and the high propor-
tion of understaged or unstaged patient 
in their series; this, in our opinion, is a 
strong methodological bias with a high 
potential of hampering the subsequent 
multivariate analysis planned to dissect, 
in detail, the role of staging and surgi-
cal approach on survival. The flickering 
of values defining the role of pathologi-
cal stage as a prognostic factor in this 
series would recommend a cautious 
approach the coherence of the clinical 
and pathological TNM values, in par-
ticular regarding their capacity to predict 
the outcome—especially in the long-
term setting where curves do abate and 
flat—and by consequence to substanti-
ate, and thus justify, the indication for a 
more extensive surgical approach. More 
information around this issue would add 
precious knowledge on the natural his-
tory of the MPM, which is indeed pecu-
liar.5 We would furthermore appreciate a 
deeper analysis of the unstaged/under-
staged cases taken separately from those 
where data on staging where, preopera-
tively, complete. Anyway, if in the future 
only EP/D procedures will be offered 
to patients with MPM with “curative” 
or “palliative” intent (as in their con-
clusions Bovolato et al3 foresee) in the 
context of a multimodal treatment, what 
could be the usefulness of an extensive 
staging apart from excluding from sur-
gery patients with unresectable disease 
or with N-positive or M-positive status?
We would conclude constructively 
by inviting Bovolato et al3 to go deeper 
into the analysis in-line with the dis-
cussed points and provide the community 
with further interesting details. As well, 
we believe that experts’ dialogue—given 
the level of complexity of conflicting evi-
dences on this subject, in turn, generated 
by strong determinants as such as the het-
erogeneity of therapeutic choices—is still 
the best way to move on to resolve the 
large grey areas of knowledge for man-
agement and clinical decision in this field.
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To the Editor:
Carbonelli et al. made a very 
important point, focusing on the lack 
of evidence regarding the best surgi-
cal treatment to manage malignant 
pleural mesothelioma (MPM) patients. 
The only prospective randomized trial 
published in the literature showed no 
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We addressed the understaged 
patients, when we reported the sur-
vival rates stage by stage as part of the 
descriptive results of our populations, 
and not surprisingly there were no cor-
relations between clinical staging and 
overall survival. In nonstaged patients, 
the only reliable characteristics as 
showed by our article in the multivari-
ate analysis were age, histology, and 
chemotherapy treatment.
Pathological staging was more 
reliable and in our study it was less 
affected by missing values (75 of 503 
[14.9%]); as shown in Figure 1, the 
relative risk of death between the sur-
gical approaches is qualitatively (sur-
vival curve PD over survival curve 
EPP) and quantitatively (HR estimated 
as ratio of median overall survival 
under assumption of exponential dis-
tribution) similar for stages I, II, and 
III. This behavior is drastically differ-
ent for stage IV. We pointed out that 
the results regarding stage IV should 
be considered very carefully due to the 
missing data and the small sample size 
of stage IV patients, before consider-
ing EPP a better surgical option for 
advanced stage MPM.
We strongly believe that a presur-
gical staging with computed tomogra-
phy and positron emission tomography 
is still necessary to exclude patients 
with extensive N2 disease or M disease 
or obvious T4 disease from surgery and 
avoid unnecessary surgical exploration, 
but we still need to improve the accu-
racy of the clinical staging in MPM. 
We do not recommend routinely preop-
erative mediastinal staging or staging 
laparoscopy, even though they could be 
necessary to rule out the resectability in 
selected patients.
We agree that discussion is 
fundamental in such a complex dis-
ease to manage, as mesothelioma, but 
what we really need is prospective tri-
als comparing different treatments. 
MARS2 trail in United Kingdom and 
PASS trial in Italy can help to assess 
the role of PD compared with chemo-
therapy alone in the management of 
MPM.
Andrea Billè, MD
Luca Porcu, PhD
Department of Thoracic Surgery
Guy's Hospital
London, United Kingdom 
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FIGURE 1.  Kaplan Meier overall survival curves for patients underwent EPP vs PD 
analyzed by stage.
